Avanos Medical (NYSE:AVNS) Issues FY18 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $1.75-1.90 for the period, compared to the Thomson Reuters consensus estimate of $1.75.

AVNS traded up $0.04 during trading on Friday, reaching $72.10. The stock had a trading volume of 231,700 shares, compared to its average volume of 387,354. The stock has a market cap of $3.41 billion, a PE ratio of 30.69 and a beta of 1.60. The company has a quick ratio of 2.18, a current ratio of 2.48 and a debt-to-equity ratio of 0.19. Avanos Medical has a one year low of $41.51 and a one year high of $72.93.

AVNS has been the topic of a number of research analyst reports. Zacks Investment Research raised Avanos Medical from a hold rating to a buy rating and set a $71.00 target price on the stock in a research note on Thursday, August 9th. Morgan Stanley upped their price target on shares of Avanos Medical from $58.00 to $60.00 and gave the company an underweight rating in a research report on Wednesday, August 8th. KeyCorp upped their price target on shares of Avanos Medical from $66.00 to $75.00 and gave the company an overweight rating in a research report on Wednesday, August 8th. Finally, Raymond James upgraded shares of Avanos Medical from a market perform rating to an outperform rating in a research report on Tuesday, August 21st.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Featured Story: Stop Order

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply